newsfilter
← Latest News
GlobeNewswire·

FDA Grants Fast Track Designation for Ambrx's ARX517 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO, July 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the "Company") (NASDAQ:AMAM), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ambrx's